The FLUYDO NC Post Market Clinical Follow-up Study
Multicenter Prospective Registry in Current Clinical Practice With the Non-compliant Coronary Angioplasty Balloon Catheter. The FLUYDO NC Post Market Clinical Follow-up Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Alvimedica
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Turkish citizen,
- ≥18 years of age,
- Has indication for percutaneous transluminal coronary angioplasty (PTCA),
- Has indication to treat obstructive lesions of a native coronary artery or aortocoronary bypass or needs post dilatation of coronary stent
- Fluydo NC using in the primary lesion treated during the procedure by the decision physician,
- Has signed and dated the informed consent.
Exclusion Criteria:
- Has a previous diagnosis of coronary artery spasm in the absence of a significant stenosis.
- Needs the device use in an unprotected left main coronary artery
- Device use has not consistent with Instructions for Use.
- Participating in another medical device or pharmaceutical clinical trial.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Device success
Time Frame: immediately after interventional procedure
|
immediately after interventional procedure
|
|
Successful inflation, achievement of appropriate diameter, and deflation of the balloon
Time Frame: immediately after interventional procedure
|
immediately after interventional procedure
|
|
Decrease in the percent stenosis after balloon procedure
Time Frame: immediately after interventional procedure
|
immediately after interventional procedure
|
|
No perforation, flow-limiting dissection or reduction in Thrombolysis in Myocardial Infarction (TIMI) flow grade
Time Frame: immediately after interventional procedure
|
immediately after interventional procedure
|
|
No life-threatening arrhythmias (sustained ventricular tachycardia, ventricular fibrillation)
Time Frame: immediately after interventional procedure
|
immediately after interventional procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Procedural success: Measurement: Percentage of device success without major adverse cardiovascular events (MACE) (composite of all death, myocardial infarction (MI), and clinically indicated target lesion revascularization (CI-TLR))
Time Frame: Discharge or 48 hours after index procedure, whichever happens first
|
Discharge or 48 hours after index procedure, whichever happens first
|
|
Rate of Target Lesion Failure (TLF) Measurement: Percentage of a composite of cardiac death, target vessel myocardial infarction (TV-MI), and CI-TLR.
Time Frame: discharge or 48 hours after index procedure, whichever happens first
|
discharge or 48 hours after index procedure, whichever happens first
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C32103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.